Is new always better than old? The development of human vaccines for anthrax

Human Vaccines

Volumn 5, Issue 12, 2009, Pages

  Baillie, Leslie W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Anthrax; Bacillus anthracis; Immunity; Pathogenicity; Vaccine

Indexed keywords

AMOXICILLIN; ANTHRAX VACCINE; ANTITOXIN; CHLORAMPHENICOL; CIPROFLOXACIN; DNA VACCINE; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; MYELOID DIFFERENTIATION FACTOR 88; PENICILLIN G; RECOMBINANT F1 V; RECOMBINANT PROTECTIVE ANTIGEN; RECOMBINANT PROTECTIVE ANTIGEN 102; SPARVAX; STERNE VACCINE; TC83; TETRACYCLINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; ANTHRAX TOXIN; BACTERIAL ANTIGEN; BACTERIAL TOXIN; IMMUNOLOGICAL ADJUVANT; RECOMBINANT PROTEIN;

ANTHRAX; ANTIBIOTIC SENSITIVITY; ANTIBODY RESPONSE; BACILLUS ANTHRACIS; BACTERIAL VIRULENCE; BIOLOGICAL WARFARE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MASS IMMUNIZATION; PROPHYLAXIS; REVIEW; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; INJECTION;

ADJUVANTS, IMMUNOLOGIC; ANTHRAX; ANTHRAX VACCINES; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BIOTERRORISM; CLINICAL TRIALS AS TOPIC; HUMANS; INJECTIONS; RECOMBINANT PROTEINS;

EID: 85046915570     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.9777     Document Type: Review

References (137)

1. Turnbull PC. Anthrax vaccines: past, present and future. Vaccine 1991; 9:533-9.
2. th edn ed.,), Edward Amold Ltd., London 1975; 1672-94.
3. Koch R. Beitr z Biol d. Pflanzen 1876; 2:277-310.
4. Pasteur L. De I'attenuation des virus el de leur retour & la virulence. CR Acad Sci Agric Bulg 1881; 92:429-35.
5. Tigertt WD. Anthrax. William Smith Greenfield MD, F.R.C.P., Professor Superintendent, the Brown Animal Sanatory Institution (1878-81). Concerning the priority due to him for the production of the first vaccine against anthrax. J Hyg (Lond) 1980; 85:415-20.
6. Metchnikoff E. Immunity in infective diseases, Binnie FG. (transl.), Cambridge University Press, London 1905.
7. Zilinskas RA. Iraq's Biological Weapons, The past as future? JAMA 1997; 278:418-24.
8. Keim P, Smith KL, Keys C, Takahashi H, Kurata T, Kaufmann A. Molecular investigation of the Aum Shinrikyo anthrax release in Kameido, Japan. J Clin Microbiol 2001; 39:4566-7.
9. Atlas RM. Bioterriorism: from threat to reality. Annu Rev Microbiol 2002; 56:167-85.
10. Kolstø AB, Tourasse NJ, Okstad OA. What Sets Bacillus anthracis Apart from Other Bacillus Species? Annu Rev Microbiol 2009; Epub ahead of print.
11. Read TD, Peterson SN, Tourasse N, Baillie LW, Paulsen IT, Nelson KE, et al. The Genome Sequence of Bacillus anthracis Ames and Comparison to Closely Related Bacteria. Nature 2003; 423:81-6.
12. Hoffmaster AR, Ravel J, Rasko DA, Chapman GD, Chute MD, Marston CK, et al. Identification of Anthrax Toxin Genes in a Bacillus cereus Associated with an Illness Resembling Inhalation Anthrax. Proc Natl Acad Sci USA 2004; 101:8449-54.
13. Little SF, Ivins BE. Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect 1999; 2:131-9.
14. Makino SI, Watarai M, Cheun H-I, Shirahata T, Uchida I. Effect of the Lower Molecular Capsule Released from the Cell Surface of Bacillus anthracis on the Pathogenesis of Anthrax. J Infect Dis 2002; 186:227-33.
15. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JAT. Identification of the Cellular Receptor for Anthrax Toxin. Nature 2001; 414:225-9.
16. Rainey GJA, Young JAT. Antitoxins: Novel Strategies to Target Agents of Bioterrorism. Nat Rev Micro 2004; 2:721-6.
17. Petosa C, Collier RJ, Klimpel KR, Leppla SH, Liddington RC. Crystal Structure of the Anthrax Toxin Protective Antigen. Nature 1997; 385:833-8.
18. Leppla SH. The Anthrax Toxin Complex. In Alouf JE, Freer JH, eds. Sourcebook of Bacterial Protein Toxins, New York: Academic Press 1991; 277-302.
19. Panchal RG, Halverson KM, Ribot W, Lane D, Kenny T, Abshire TG, et al. Purified Bacillus anthracis Lethal Toxin Complex Formed in Vitro and During Infection Exhibits Functional and Biological Activity. J Biol Chem 2005; 280:10834-9.
20. Smith H, Keppie J. Observations on Experimental Anthrax; Demonstration of a Specific Lethal Factor Produced in vivo by Bacillus anthracis. Nature 1954; 173:869-70.
21. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998; 280:734-7.
22. Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C. Anthrax Lethal Factor Cleaves Mkk3 in Macrophages and Inhibits the Lps/Ifn-γ- Induced Release of NO and Tnfα. FEBS Letters 1999; 462:199-204.
23. Baldari CT, Tonello F, Paccani SR, Montecucco C. Anthrax toxins: A paradigm of bacterial immune suppression. Trends Immunol 2006; 27:434-40.
24. Boyden ED, Dietrich WF. Nalp1b Controls Mouse Macrophage Susceptibility to Anthrax Lethal Toxin. Nat Gen 2006; 38:240-4.
25. O'Brien J, Friedlander A, Dreier T, Ezzell J, Leppla S. Effects of anthrax toxin components on human neutrophils. Infect Immun 1985; 47:306-10.
26. Wright GG, Mandell GL. Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide. J Exp Med 1986; 164:1700-9.
27. Moayeri M, Leppla SH. The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol 2004; 7:19-24.
28. Sherer K, Li Y, Cui X, Eichacker PQ. Lethal and Edema Toxins in the Pathogenesis of Bacillus anthracis Septic Shock: Implications for Therapy. Am J Respir Crit Care Med 2007; 175:211-21.
29. Ivanovics G, Bruckner V. Chemische und immunologische studien uber den mechanismus der milzbrandinfecktion und immunitat die chemische struktur der kapselsubstanz des milzbrandbazillus und der serolisch identischen spezifichen substanz des bacillus mesentericus. Z Immunitaetsforsch. Experimental Therapeutics 1937; 90:304.
30. Hoffmaster AR, Koehler TM. Control of virulence gene expression in Bacillus anthracis. J Appl Microbiol 1999; 87:279-81.
31. Baillie L, Read TD. Bacillus anthracis, a bug with attitude! Curr Opin Microbiol 2001; 4:78-81.
32. Mignot T, Mock M, Robichon D, Landier A, Lereclus D, Fouet A. The Incompatibility between the PlcR- and Atxa-Controlled Regulons May Have Selected a Nonsense Mutation in Bacillus anthracis. Mol Microbiol 2001; 42:1189-98.
33. Baillie L, Hibbs S, Tsai P, Cao GL, Rosen GM. Role of superoxide in the germination of Bacillus anthracis endospores. FEMS Microbiol Lett 2005; 245:33-8.
34. Redmond C, Baillie LW, Hibbs S, Moir AJ, Moir A. Identification of proteins in the exosporium of Bacillus anthracis. Microbiology 2004; 150:355-63.
35. Weaver J, Kang TJ, Raines KW, Cao GL, Hibbs S, Tsai P, et al. Protective role of Bacillus anthracis exosporium in macrophage-mediated killing by nitric oxide. Infect Immun 2007; 75:3894-901.
36. Raines KW, Kang TJ, Hibbs S, Cao GL, Weaver J, Tsai P, et al. Importance of nitric oxide synthase in the control of infection by Bacillus anthracis. Infect Immun 2006; 74:2268-76.
37. Mayer-Scholl A, Hurwitz R, Brinkmann V, Schmid M, Jungblut P, Weinrauch Y, et al. Human neutrophils kill Bacillus anthracis. PLoS Pathog 2005; 1:23. Epub 2005.
38. Baillie LWJ. Bacillus anthracis. In Encyclopaedia of Food Microbiology. Batt CA, Robinson RK, Patel PD, Eds. London: Academic Press 2000; 1:129-35.
39. Baillie LW. Past, imminent and future human medical countermeasures for anthrax. J Appl Microbiol 2006; 101:594-606.
40. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, et al. Postexposure Prophylaxis against Experimental Inhalation Anthrax. J Infect Dis 1993; 167:1239-43.
41. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, et al. Investigation of Bioterrorism-Related Anthrax, United States, 2001: Epidemiologic Findings. Emerg Infect Dis 2002; 8:1019-28.
42. Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, et al. Antimicrobial post exposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002; 8:1124-32.
43. Baillie L. The development of new vaccines against Bacillus anthracis. J Appl Microbiol 2001; 91:609-13.
44. Adone R, Pasquali P, La Rosa G, Marianelli C, Muscillo M, Fasanella A, et al. Sequence analysis of the genes encoding for the major virulence factors of Bacillus anthracis vaccine strain 'Carbosap'. J Appl Microbiol 2002; 93:117-21.
45. Sterne M, Robinson EM, Nicol J. The use of saponin spore vaccine for inoculation against anthrax in South Africa. Onderstepoort J Vet Sci An Ind 1939; 12:279-302.
46. Hambleton P, Carman JA, Melling J. Anthrax: the disease in relation to vaccines. Vaccine 1984; 2:125-32.
47. Sirard JC, Weber M, Duflot E, Popoff MR, Mock M. A recombinant Bacillus anthracis strain producing the Clostridium perfringens Ib component induces protection against iota toxins. Infect Immun 1999; 65:2029-33.
48. Shlyakhov N, Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine 1994; 12:727-30.
49. Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, Little S, et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, routechange comparison study in humans. Vaccine 2002; 20:1412-20.
50. Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008; 300:1532-43.
51. Klinman DM, Xie H, Ivins BE. CpG Oligonucleotides Improve the Protective Immune Response Induced by the Licensed Anthrax Vaccine. Ann NY Acad Sci 2006; 1082:137-50.
52. Belton FC, Strange RE. Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production. Brit J Exp Path 1954; 35:144-52.
53. Broster MG, Hibbs SE. Protective Efficacy of Anthrax Vaccines against aerosol challenge. In Proceedings of the International Workshop on Anthrax, 11-12 April, 1989, Winchester UK. Salisbury Medical Bulletin 1990; 68:91-2.
54. Phipps AJ, Premanandan C, Barnewall RE, Lairmore MD. Rabbit and nonhuman primate models of toxintargeting human anthrax vaccines. Microbiol Mol Biol Rev 2004; 68:617-29.
55. Darlow HM, Belton FC, Henderson DW. The use of anthrax antigen to immunise man and monkey. Lancet 1956; 11:476-9.
56. Hepburn MJ, Dyson EH, Simpson AJH, Brenneman KE, Bailey N, Wilkinson L, et al. Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine. Vaccine 2007; 25:6089-97.
57. Baillie L, Townend T, Walker N, Eriksson U, Williamson D. Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol Med Microbiol 2004; 42:267-70.
58. Baillie L, Hibbs S, Tsai P, Cao GL, Rosen GM. Role of superoxide in the germination of Bacillus anthracis endospores. FEMS Microbiol Lett 2005; 245:33-8.
59. Brenneman KE, Dognanay M, Akmal A, Goldman S, Galloway DR, Mateczun AJ. The Early Humoral Immune Response to Bacillus anthracis Toxins in Patients Infected with Cutaneous Anthrax (In preparation).
60. Galloway D, Liner A, Legutki J, Mateczun A, Barnewall R, Estep J. Genetic immunization against anthrax. Vaccine 2004; 22:1604-8.
61. Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 2004; 101:13601-6.
62. Wasserman GM, Grabenstein JD, Pittman PR, Rubertone MV, Gibbs PP, Wang LZ. Analysis of adverse events after anthrax immunization in US Army medical personnel. J Occup Environ Med 2003; 45:222-33.
63. Enstone JE, Wale MC, Nguyen-Van-Tam JS, Pearson JC. Adverse medical events in British service personnel following anthrax vaccination. Vaccine 2003; 28:1348-5.
64. Anders M, Carlsson RM, Granstroem M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 1999; 17:2067-72.
65. Food and Drug Administration. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. 21CFR 314 and 601. U.S. Food and Drug Administration. Rockville, MD: Department of Health and Human Services. 2002.
66. Beedham RJ, Turnbull PC, Williamson ED. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 2001; 19:4409-16.
67. Little SF, Ivins BE, Fellows PF, Pitt ML, Norris SL, Andrews GP. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 2004; 22:422-30.
68. Baillie LWJ, Rodriguez AL, Moore S, Atkins HS, Feng C, Nataro JP, Pasetti MF. Towards a human oral vaccine for anthrax: The utility of a Salmonella typhi Ty21a-based prime-boost immunization strategy. Vaccine 2008; 26:6083-91.
69. Reason D, Liberato J, Sun J, Keitel W, Zhou J. Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infect Immun 2009; 77:2030-5.
70. Flick-Smith HC, Eyles JE, Hebdon R, Waters EL, Beedham RJ, Stagg TJ, et al. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun 2002; 70:2022-8.
71. Stokes MG, Titball RW, Neeson BN, Galen JE, Walker NJ, Stagg AJ, et al. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect Immunity 2007; 75:1827-34.
72. Baillie L, Moore S, Huwar T, Atkins H, Nataro J, Pasetti P. Anthrax Vaccine Candidate based on the key protective regions of Protective Antigen and Lethal Factor (manuscript in preparation).
73. Rosovitz MJ, Schuck P, Varughese M, Chopra AP, Mehra V, Singh Y, et al. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem 2003; 278:30936-44.
74. Cote CK, Rossi CA, Kang AS, Morrow PR, Lee JS, Welkos SL. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb Pathog 2005; 38:209-25.
75. Kang TJ, Fenton MJ, Weiner MA, Hibbs S, Basu S, Baillie L, Cross AS. Murine macrophages kill the vegetative form of Bacillus anthracis. Infect Immun 2005; 73:7495-501.
76. Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA. Development of novel vaccines against anthrax in man. J Biotechnol 1996; 44:155-60. Review
77. Pomerantsev AP, Staritsin NA, Mockov YuV, Marinin LI. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 1997; 15:1846-50.
78. Ivins BE, Fellows PF, Pitt MLM, Estep JE, Welkos SL, Worsham PL, Friedlander AM. Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Sal Med Bull 1996; 87:125-6.
79. Tross D, Klinman DM. Effect of CpG Oligonucleotides on Vaccine-Induced B Cell Memory J Immunol 2008; 181:5785-90.
80. Quinn CP, Dull PM, Semenova V, Li H, Crotty S, Taylor TH, et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 2004; 190:1228-36.
81. Glomski IJ, Corre JP, Mock M, Goossens PL. Cutting Edge: IFN-Producing CD4 T Lymphocytes Mediate Spore-Induced Immunity to Capsulated Bacillus anthracis. J Immunol 2007; 178:2646-50.
82. Walberg K, Baron S, Poast J, Schwartz B, Izotova L, Pestka S, Peterson JW. Interferon protects mice against inhalation anthrax. J Interferon Cytokine Res 2008; 28:597-601.
83. Sabet M, Cottam HB, Guiney DG. Modulation of cytokine production and enhancement of cell viability by TLR7 and TLR9 ligands during anthrax infection of macrophages. FEMS Immunol Med Microbiol 2006; 47:369-79.
84. Hughes MA, Green CS, Lowchyj L, Lee GM, Grippe VK, Smith MF Jr, et al. MyD88-dependent signaling contributes to protection following Bacillus anthracis spore challenge of mice: implications for Toll-like receptor signaling. Infect Immun 2005; 73:7535-40.
85. Friedlander AM, Welkos SL, Ivins BE. Anthrax vaccines. Curr Top Microbiol Immunol 2002; 271:33-60.
86. Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 2006; 24:5950-9.
87. Williamson ED, Hodgson I, Walker NJ, Topping AW, Duchars MG, Mott JM, et al. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect Immun 2005; 73:5978-87.
88. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005; 366:749-62.
89. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59:587-635.
90. Hull AK, Criscuolo CJ, Mett V, Groen H, Steeman W, Westra H, et al. Human-derived, plant-produced monoclonal antibody for the treatment of anthrax. Vaccine 2005; 23:2082-6.
91. Koya V, Moayeri M, Leppla SH, Daniell H. Plant-based vaccine: mice immunized with chloroplastderived anthrax protective antigen survive anthrax lethal toxin challenge. Infect Immun 2005; 73:8266-74.
92. Chichester JA, Musiychuk K, de la Rosa P, Horsey A, Stevenson N, Ugulava N, et al. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 2007; 25:3111-4.
93. Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun 2000; 68:1196-201.
94. Aloni-Grinstein R, Gat O, Altboum Z, Velan B, Cohen S, Shafferman A. Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun 2005; 73:4043-53.
95. Zegers ND, Kluter E, van Der Stap H, van Dura E, van Dalen P, Shaw M, Baillie L. Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax. J Appl Microbiol 1999; 87:14-30.
96. Garmory HS, Brown KA, Titball RW. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiology Reviews 2002; 26:339-53.
97. Osorio M, Wu Y, Singh S, Merkel TJ, Bhattacharyya S, Blake MS, Kopecko DJ. Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge. Infect Immun 2009; 77:1475-82.
98. Galen JE, Chinchilla M, Pasetti MF, Wang JY, Zhao L, Arciniega-Martinez I, et al. Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine. J Infect Dis 2009; 199:326-35.
99. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004; 25:98-104.
100. Pasetti MF, Resendiz-Albor A, Ramirez K, Stout R, Papania M, Adams RJ, et al. Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques. Clin Pharmacol Ther 2007; 82:672-85.
101. Gaur R, Gupta PK, Banerjea AC, Singh Y. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin. Vaccine 2002; 20:2836-9.
102. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 2003; 170:5636-43.
103. Sloat BR, Shaker DS, Le UM, Cui Z. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens. FEMS Immunol Med Microbiol 2008; 52:169-79.
104. Klas SD, Petrie CR, Warwood SJ, Williams MS, Olds CL, Stenz JP, et al. A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Vaccine 2008; 26:5494-502.
105. Partidos CD, Beignon AS, Mawas F, Belliard G, Briand JP, Muller S. Immunity under the skin: potential application for topical delivery of vaccines. Vaccine 2003; 21:776-80.
106. Kenney RT, Yu J, Guebre-Xabier M, Frech SA, Lambert A, Heller BA, et al. Induction of protective immunity against lethal anthrax challenge with a patch. J Infect Dis 2004; 190:774-82.
107. Peachman KK, Rao M, Alving CR, Burge R, Leppla SH, Rao VB, et al. Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infect Immun 2006; 74:794-7.
108. Zhang J, Shi Z, Kong FK, Jex E, Huang Z, Watt JM, et al. Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infect Immun 2006; 74:3607-17.
109. Mikszta JA, Sullivan VJ, Dean C, Waterston AM, Alarcon JB, Dekker JP, 3rd, et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis 2005; 191:278-88.
110. Galloway DR, Baillie L. DNA vaccines against anthrax. Expert Opin Biol Ther 2004; 4:1661-7.
111. Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines. Dev Biol Stand 1998; 95:43-53.
112. Keitel WA, Treanor JJ, El Sahly HM, Evans TG, Kopper S, Whitlow V. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccine 2009; 5:Epub ahead of print.
113. Luxembourg A, Hannaman D, Nolan E, Ellefsen B, Nakamura G, Chau L, et al. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 2008; 26:5216-22.
114. Park YS, Lee JH, Hung CF, Wu TC, Kim TW. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun 2008; 76:1952-9.
115. Midha S, Bhatnagar R. Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses. Eur J Immunol 2009; 39:159-77.
116. Midha S, Bhatnagar R. Genetic immunization with GPI-anchored anthrax protective antigen raises combined CD1d- and MHC II-restricted antibody responses by natural killer T cell-mediated help. Eur J Immunol 2009; 39:159-77.
117. Tan YNR, Hackett NR, Boyer JL, Crystal RG. Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum Gene Ther 2003; 14:1673-82.
118. Lee JS, Groebner JL, Hadjipanayis AG, Negley DL, Schmaljohn AL, Welkos SL, et al. Multiagent vaccines vectored by Venezuelan Equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 2006; 24:6886-92.
119. Baker AH. Adenovirus Toxicity and Tropism In Vivo: Not as Simple as A, B, C (or D, E, F) Mol Ther 2007; 15:2061-2.
120. Hashimoto M, Boyer JL, Hackett NR, Wilson JM, Crystal RG. Induction of Protective Immunity to Anthrax Lethal Toxin with aNonhuman Primate Adenovirus-Based Vaccine in the Presence of Preexisting Anti-Human Adenovirus Immunity. Infect Immun 2005; 73:6885-91.
121. Manayani DJ, Thomas D, Dryden KA, Reddy V, Siladi ME, Marlett JM, et al. A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. PLoS Pathog 2007; 3:142.
122. Brossier F, Levy M, Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 2002; 70:661-4.
123. Brahmbhatt TN, Darnell SC, Carvalho HM, Sanz P, Kang TJ, Bull RL, et al. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect Immun 2007; 75:5240-7.
124. Cybulski RJ Jr, Sanz P, McDaniel D, Darnell S, Bull RL, O'Brien AD. Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen. Vaccine 2008; 26:4927-39.
125. Kubler-Kielb J, Vinogradov E, Haijing Hu H, Leppla SH, Robbins JB, Schneerson R. Saccharides cross-reactive with Bacillus anthracis spore glycoprotein as an anthrax vaccine component. Proc Natl Acad Sci USA 2008; 105:8709-12.
126. Gat O, Grosfeld H, Ariel N, Inbar I, Zaide G, Broder Y, et al. Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen. Infect Immun 2006; 74:3987-4001.
127. Chitlaru T, Gat O, Grosfeld H, Inbar I, Gozlan Y, Shafferman A. Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome. Infect Immun 2007; 75:2841-52.
128. With the exception of PA none of the proteins were shown to be protective. (unpublished data Baillie lab).
129. Cowan GJ, Atkins HS, Johnson LK, Titball RW, Mitchell TJ. Immunisation with anthrolysin O or a genetic toxoid protects against challenge with the toxin but not against Bacillus anthracis. Vaccine 2007; 25:7197-205.
130. Heffernan BJ, Thomason B, Herring-Palmer A, Hanna P. Bacillus anthracis anthrolysin O and three phospholipases C are functionally redundant in a murine model of inhalation anthrax. FEMS Microbiol Lett 2007; 271:98-105.
131. Skoble J, Beaber JW, Gao Y, Lovchik JA, Sower LE, Liu W, et al. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax. Infect Immun 2009; 77:1649-63.
132. Griffin K, Bedford R, Townson K, Phillpotts R, Funnell S, Morton M, et al Protective efficacy of a recombinant plague vaccine when co-administered with another sub-unit or live attenuated vaccine. FEMS Immunol Med Microbiol 2005; 43:425-30.
133. Williamson ED, Bennett AM, Perkins SD, Beedham RJ, Miller J, Baillie LW. Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague. Vaccine 2002; 20:2933-41.
134. Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003; 21:4071-80.
135. US Provisional Patent Salmonella based oral vaccine for anthrax Inventor: Baillie LWJ 14.11.05.
136. Sabhnani L, Manocha M, Sridevi K, Shashikiran D, Rayanade R, Rao DN. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles. FEMS Immunol Med Microbiol 2003; 38:215-29.
137. Sette A, Fleri W, Peters B, Sathiamurthy M, Bui HH, Wilson S. A roadmap for the immunomics of category A-C pathogens. Immunity 2005; 22:155-61.